All News
JIA Pathogenesis Related to Neutrophils and Epigenetics
Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).
Read ArticleObesity Protects Men from Rheumatoid Arthritis
Researchers from Malmo, Sweden have analyzed data from 383 patients, taken from two population based health surveys with a total of 50,705 participants, and found there is a strong association between a high BMI in men and a lower risk of developing rheumatoid arthritis (RA).
Read ArticleDrug Safety Reports & FDA Updates – August 2015
Safety reports from literature include long-term safety of rituximab, rituximab-induced neutropenia, tabalumab (Anti-BAFF Mab) results from the ILLUMINATE trial, colchicine toxicity increased in CKD patients, FDA updates and drug labeling changes, and more.
Read ArticleSCOT Study Shows NSAID Safety
Since the 2005 FDA hearing that resulted in the removal of Vioxx and Bextra from the US market, the safety of nonselective NSAIDs (nsNSAIDs) and selective Cox-2 inhibitors (e.g., celecoxib) has been repeatedly questioned, often without new or substantive data.
Read ArticleHospitalized Infections are Higher with the Second Biologic
Using Medicare claims data on 189,326 RA patients, researchers at the University of Alabama at Birmingham examined the rates of hospitalized infections in previously biologic-treated RA patients and compared rates in cohorts starting new treatment with etanercept, adalimumab, certolizum
Read ArticleC5orf30 Gene is a Negative Regulator of Tissue Damage in Rheumatoid Arthritis
PNAS has reported the work of an international team of scientists from the University College Dublin and the University of Sheffield, who have studied DNA samples and biopsy samples from joints of over 1,000 rheumatoid arthritis patients in the UK and Ireland and determined the C5orf30 gene to be
Read ArticleEarly RA and the Chance of DMARD-Free Remission
Early and aggressive treatment of rheumatoid arthritis has become the mantra for most who manage the disease and hope to achieve optimal outcomes - including remission.
Read ArticleCancer Risk Is Both Increased and Decreased in RA
Rheumatoid arthritis patients are often said to have no or a low risk of cancer.
Read ArticlePriorities for NIAMS Research Funding
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Read ArticleLong-Term Safety of Rituximab
Rituximab has been used for years with good efficacy, but with several safety concerns. Van Vollenhoven and colleagues have published the cumulative clinical trial safety experience of RTX wherein 3595 patients 1–20 (average - 4) courses over 11 years [14,816 patient-years (PY)].
Read ArticleSpecialty Society Guidelines Must Evolve to Improve
The current JAMA issue examines the process and potential flaws of society clinical practice guidelines -a timely commentary as we await the 2015 ACR RA treatment guidelines first presented at the 2014 ACR meeting in Boston and slated for upcoming publication in Arthritis & Rheumatology
Read ArticleOsteoporosis Affects One-Quarter US Women Over 65 Years
The CDC has released data from the NHANES (National Health and Nutrition Examination Survey) analysis of 2005-2010 data regarding the population frequency of osteoporosis and osteopenia.
Read ArticleHypothyroidism is Increased in Rheumatoid Arthritis Patients
In a study that compared seropositive (RF+, CCP+) and seronegative RA with healthy participants, the frequency of thyroid antibodies was assessed.
Read ArticleDSB: Managing Methotrexate Toxicity
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
Read ArticleRituximab Induced Neutropenia
In reviewing submitted abstracts for the 2014 ACR meeting, I was surprised by several abstracts focusing on neutropenia in patients receiving rituximab.
Read ArticleCV Risk in RA: Is a New Measurement Tool the Answer?
A new expanded cardiovascular (CV) risk calculator for use in patients with rheumatoid arthritis (RA) has been developed to take into account disease-specific factors that can worsen risk, researchers reported.
Read ArticleBidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Read ArticleNSAIDs are Risky in Patients with Chronic Kidney Disease
Little is known about what happens when NSAIDs are used in patients with chronic kidned disease (CKD), especially those with hypertension.
Read ArticleLipid Levels and CV Events in RA
Rheumatoid arthritis not only affects the joints but can also increase risk for cardiovascular disease. The mechanism of the increased risk of cardiovascular disease in rheumatoid arthritis remains uncertain.
Read ArticleMen and Blacks Undertreated for Osteoporosis
Using claims data from 36,965 patients in an Indiana database, researchers found women (OR 1.86) and non-black patients (OR 1.52) were more likely to be treated (p<0.001) for osteoporosis.
Read Article